Examples of complement pathway inhibitors FDA-approved or in phase III clinical trials for the management of PNH. Pegcetacoplan is a complement C3 inhibitor administered twice weekly as a subcutaneous infusion. Extravascular hemolysis due to opsonization of PNH erythrocytes with complement C3 fragments may account for persistent anemia in patients with PNH on terminal complement inhibition (eculizumab or ravulizumab). By inhibiting proximal complement, pegcetacoplan targets both intravascular and extravascular hemolysis.